SURTAVI

Surgical or Transcatheter Aortic-valve replacement in intermediate-risk patients - The New England Journal of Medicine - 2017

Brief Summary:

In patients with severe, symptomatic AS at intermediate surgical risk (3-15% risk of surgical death at 30 days per STS-PROM score), transcatheter aortic valve replacement (TAVR) was found to be non-inferior to surgical aortic valve replacement (SAVR) with respect to all-cause mortality and disabling stroke at 2 years. SAVR was associated with a marginally higher peri-operative stroke rate while TAVR was associated with a modest increase in hospitalizations related to aortic valvular disease at 2 years.

Reference:
http://www.ncbi.nlm.nih.gov/pubmed/28304219